莫德纳(Moderna)周三宣布撤回其流感 / 新冠双价疫苗 mRNA-1083 的上市申请,导致股价开盘后下跌 4.5%。这一决定背后,既反映了药企在复杂监管环境下的战略调整,也凸显了后疫情时代疫苗研发面临的新挑战。一、临床数据积极却撤回申请:监管沟通遇阻尽管莫德纳在 5 月初公布的 III 期数据显示,mRNA-1083 诱导的针对流感毒株和新冠 Omicron XBB.1.5 变种的抗体水平...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.